The company shared early evidence of the potential of its approach to improve newborn screening for immune disorders, and to offer new tools for other areas like HIV monitoring.
The firm has partnered with the University of Surrey to validate and potentially commercialize a test that detects mRNA biomarkers from patient urine samples.
Running on the Biocartis Idylla platform, Immunexpress' Septicyte test will detect sepsis in patients in as little as an hour.
Biocartis will help develop and commercialize Immunexpress' Septicyte test to run on the Idylla platform.
Investigators characterized expression activity in kidney grafts from a group of transplant recipients who remained rejection-free without immunosuppression.
Carrier screens for cystic fibrosis, fragile X syndrome, and spinal muscular atrophy detected carrier status in one in 20 individuals and led to diagnoses in seven pregnancies.
The test, miRpredX 31-3p, is a positive theranostic test that quantifies the expression of miR-31-3p in FFPE using RT-qPCR technology.
Among its business highlights for the quarter, the firm established coverage for the Afirma genomic sequencing classifier by all major insurance plans.
The assay is based on real-time reverse transcriptase PCR that will identify Zika in human serum or urine.
In PLOS this week: locus near OAS1 linked to Sjogren's syndrome, rotavirus reassortment events uncovered by sequencing, and more.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.